Related Experiment Video
Updated: Jun 18, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
A multidisciplinary approach to fertility-sparing therapy for a rare vulvar tumor
Cary L Dicken1, Harry J Lieman, Ashlesha K Dayal
1Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Objective:
Case report of a young woman with a rare vulvar malignancy who received treatment with a personalized multidisciplinary approach to balance management of her malignancy without compromising survival with her desire for future pregnancy.
Design:
Case report.
Setting:
University hospital.
Patient(S):
A 33-year-old woman, gravida 2, para 1-0-1-1, who had a diagnosis of synovial cell sarcoma of the vulva and who desired future fertility.
Intervention(S):
At multiple steps, treatment was planned to try to maximize fertility preservation without potentially affecting initial treatment, which included a radical hemivulvectomy with bilateral lymph node dissection, brachytherapy with interstitial needles (20 Gy), and external beam radiation therapy (50 Gy).
Main Outcome Measure(S):
Treatment and eradication of the malignancy and achievement of a successful subsequent pregnancy and live birth.
Result(S):
The patient had no evidence of disease for 2 years after treatment. During that time she received preconception counseling by both a perinatologist and a reproductive endocrinologist. She conceived with the use of ultrasound monitoring to time intercourse specifically with ovulation from the contralateral ovary and had an uncomplicated pregnancy with a term delivery.
Conclusion(S):
By using several disciplines and subspecialists, this patient received personalized treatment for a rare cancer, focused at curing her cancer and optimizing her future fertility.
Related Concept Videos
Treatment Resistant Cancers
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of endometrial...
Treatment Resistent Cancers

